Core Viewpoint - Sai Sheng Pharmaceutical (300485.SZ) has received the "High-tech Enterprise Certificate" from the Beijing Municipal Science and Technology Commission, which allows its subsidiary, Beijing Sai Er Biological Pharmaceutical Co., Ltd., to benefit from tax incentives for high-tech enterprises [1] Group 1 - The certificate number is GR202511004935, issued on December 2, 2025, and is valid for three years [1] - This recognition is a re-certification following the expiration of the previous certificate [1] - The company will enjoy a corporate income tax rate of 15% for the years 2025, 2026, and 2027 under the national tax incentive policy for high-tech enterprises [1]

证券代码：300485 证券简称：赛升药业 公告编号：2026-003 北京赛升药业股份有限公司 关于审计机构变更项目合伙人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京赛升药业股份有限公司（以下简称"公司"）于2025年3月27日、2025 年4月21日召开第五届董事会第六次会议、2024年年度股东大会，审议通过了《关 于续聘致同会计师事务所（特殊普通合伙）为公司2025年度审计机构的议案》， 同意续聘致同会计师事务所（特殊普通合伙）（以下简称"致同所"）为公司2025 年度审计机构，具体内容详见公司于2025年3月29日在巨潮资讯网披露的《关于 续聘公司2025年度财务及内部控制审计机构的公告》（公告编号：2025-011）。 近日，公司收到致同所出具的《关于拟变更项目合伙人的沟通函》，现将有 关情况公告如下： 一、本次变更项目合伙人的基本情况 致同所作为公司 2025 年度财务报表及内部控制审计机构，原指派的项目合 伙人为刘均山。鉴于致同所内部工作调整，拟将项目合伙人由刘均山变更为闫磊。 二、本次变更的项目合伙人信息 1、基本信息 闫磊，2 ...

北京赛升药业股份有限公司 关于子公司通过高新技术企业认定的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京赛升药业股份有限公司（以下简称"公司"）子公司北京赛而生物药业 有限公司（以下简称"赛而生物"）于近日收到北京市科学技术委员会、北京市 财政局、国家税务总局北京市税务局联合颁发的《高新技术企业证书》，证书编 号为GR202511004935，发证时间为2025年12月2日，有效期为三年。 证券代码：300485 证券简称：赛升药业 公告编号：2026-002 本次高新技术企业的认定系原证书有效期满后的重新认定，根据国家对高新 技术企业税收优惠政策的相关规定，赛而生物自本次通过高新技术企业认定当年 起三年内（即 2025 年度、2026 年度、2027 年度）可享受国家关于高新技术企业 所得税优惠政策，即按 15%的税率缴纳企业所得税。本次通过高新技术企业认定 事项不会对公司当期经营业绩产生重大影响。 特此公告。 北京赛升药业股份有限公司 董 事 会 2026年1月20日 ...

Core Viewpoint - The company is focusing on increasing revenue, reducing costs, and improving efficiency to enhance capital utilization and profitability while strategically planning for future project investments [1] Group 1: Strategic Development - The company has established a group development layout based on five strategic platforms: R&D innovation platform, pharmaceutical industry chain innovation platform (including high-end formulations and oral formulations production bases, active pharmaceutical ingredient production base, and modern Chinese medicine production base), collaborative technology innovation platform, capital industry platform, and seed industry innovation platform [1]

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical (300485) reported a total of 34,157 shareholders as of January 10, 2026 [1]

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical (300485.SZ) experienced a significant drop in its stock price, with a decline of 4.11% to 11.66 yuan [2] - The company announced that shareholder Ms. Ma Li will reduce her stake by selling a total of 3.3282 million shares, which represents 0.69% of the company's total share capital [2]

Group 1 - The core point of the article highlights that Sai Sheng Pharmaceutical experienced a stock price increase of 6.39%, closing at 12.16 yuan, with a significant block trade occurring [1] - The block trade involved a total volume of 820,000 shares and a transaction amount of 8.774 million yuan, with the first transaction price at 10.70 yuan, reflecting a premium rate of -12.01% [1] - The buyer was China Galaxy Securities Co., Ltd., and the seller was Industrial Securities Co., Ltd., indicating active trading interest in the stock [1] Group 2 - Over the past three months, the stock has recorded one block trade with a total transaction amount of 8.774 million yuan [1] - In the last five trading days, the stock has seen a cumulative increase of 9.06%, with a net inflow of 20.991 million yuan from major funds [1]

Core Viewpoint - The company, Sai Sheng Pharmaceutical (300485.SZ), has received a notification from Ms. Ma Li regarding her share reduction progress, indicating a planned decrease in her holdings in the company [1] Group 1 - Ms. Ma Li reduced her shareholding by a total of 3.3282 million shares [1] - The reduction represents 0.69% of the company's total share capital [1] - The share reduction occurred between November 18, 2025, and January 13, 2026, through centralized bidding and block trading methods [1]

证券代码：300485 证券简称：赛升药业 公告编号：2026-001 北京赛升药业股份有限公司 关于公司控股股东、实际控制人及一致行动人股份权益 变动触及 1%整数倍的公告 | 1.基本情况 | | | --- | --- | | 信息披露义务人 马丽 | | | 住所 | 北京市海淀区*** | | 2025 年 权益变动时间 | 11 月 18 日-2026 年 1 月 13 日 | | 权益变动过程 | 马丽女士因个人资金需求，于 2025 年 11 月 18 日-2026 年 1 月 | | 13 | 日通过集中竞价和大宗交易方式累计减持公司股份 332.82 | | | | | 司控股股东、实际控制人及一致行动人股份持有公司股份的比 | | | | --- | --- | --- | --- | --- | --- | | | | | 万股，占公司现有总股本比例为 | | 0.69%，本次减持股份后，公 | | | | 例由 57.52%减少至 | 56.83%。权益变动触及 | 1%整数倍。 | | | 股票简称 | 赛升药业 | | 股票代码 | 300485 | | | 变动方向 | 上升□ ...

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical (300485) has reported a total of 33,621 shareholders as of December 31, 2025 [1]